India is attempting to transition its pharmaceutical sector from large-scale generic manufacturing to the discovery of new drugs [1].
This shift is critical because while India dominates the global supply of affordable medicine, it remains dependent on external breakthroughs for new treatments. Moving into drug discovery would allow the nation to lead medical innovation rather than simply scaling existing formulas.
India currently plays a massive role in the global healthcare infrastructure. The country exports 20% of the world's generic medicines [1]. Additionally, India meets more than 50% of the global demand for vaccines [1]. This capacity has established the nation as a primary hub for multinational pharmaceutical companies that utilize India for clinical testing [1].
Despite these manufacturing strengths, the transition to discovery faces a significant hurdle: funding. Current levels of research and development investment are insufficient to enable Indian scientists to lead high-risk, high-reward drug-discovery projects [1]. Without a substantial increase in financial backing, the industry is limited to producing versions of medicines discovered elsewhere [2].
Domestic manufacturers and researchers are calling for a systemic change in how pharmaceutical R&D is financed. The gap between manufacturing capability and discovery potential prevents India from contributing more significantly to breakthrough medicines that treat previously incurable diseases [1].
Industry analysts said the current model favors the low-risk production of generics over the volatile nature of original research. To bridge this gap, the sector requires a funding environment that supports the long timelines, and high failure rates, associated with discovering new molecular entities [2].
“India exports 20% of the world’s generic medicines”
India's current position as the 'pharmacy of the world' is built on volume and affordability. However, the lack of investment in original drug discovery creates a strategic vulnerability, leaving the country reliant on intellectual property from Western and East Asian markets. A successful transition to discovery would shift India's economic role from a service provider to an owner of high-value medical patents.
